NEW YORK (GenomeWeb) – Molecular diagnostics firm Signal Genetics and the University of Texas MD Anderson Cancer Center have announced an agreement to evaluate the clinical utility of Signal's MyPRS test for symptomatic multiple myeloma risk.

The microarray-based MyPRS test identifies patients with asymptomatic monoclonal gammopathies, including smoldering multiple myeloma and MGUS, with a high or low risk for rapid progression to symptomatic multiple myeloma.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.